Highest-materiality recent filing
Zymeworks authorizes $125M share repurchase program, expects cash runway beyond 2028
Board authorized up to $125M share repurchase of common stock under 2026 program.
Jazz sBLA for zanidatamab in 1L HER2+ GEA accepted with Priority Review; PDUFA target date Aug 25, 2026.
Zymeworks appoints Kristin Stafford as CFO, effective April 1, 2026
Stafford previously SVP, CAO at Royalty Pharma; brings life sciences capital markets experience.
Zymeworks secures $250M non-recourse royalty-backed note from Royalty Pharma on Ziihera royalties
Repayment from 30% of Ziihera tiered royalties; total due $412.5M if paid by Dec 2033 or $481.3M by Dec 2042.
FY2025 revenue $106.0M (+39% YoY); net loss $81.1M vs $122.7M in 2024.
Zymeworks terminates CFO, reports ~$270.6M cash; new COO and CMO appointed
CFO Leone Patterson terminated without cause Jan 9; CEO Kenneth Galbraith appointed interim CFO.
Zymeworks shifts to royalty-driven model, authorizes $125M buyback; appoints Platshon as CIO
Eligible for up to $440M in near-term milestones from Ziihera GEA approvals ($250M US, $100M EU, $75M Japan, $15M China).
Zymeworks announces positive Phase 3 results for Ziihera in first-line HER2+ GEA
Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS trend with further analysis expected mid-2026.
Zymeworks Q3 2025 revenue $27.6M, net loss narrows to $19.6M; positive ZW191 data
Revenue $27.6M (up from $16.0M YoY) driven by $25.0M J&J milestone; net loss $19.6M vs $29.9M.
Zymeworks discontinues ZW171 Phase 1 after dose escalation; benefit-risk profile unfavorable
Decision based on completed dose escalation in ovarian and NSCLC patients; MTD established but benefit-risk not supportive.
Gregory Ciongoli and Robert E. Landry appointed as directors effective Aug 10, 2025; Ciongoli as Class II, Landry as Class I; both join Audit Committee.
Zymeworks posts Q2 net income of $2.3M on revenue of $48.7M; cash runway into 2H-2027
Revenue of $48.7M in Q2 2025 vs $19.2M in Q2 2024, driven by $20M BeOne milestone and $7.5M BMS license option.
Zymeworks removes warrant cap; EcoR1 exercises for 5.1M shares, diluting by ~7%
Removed 19.99% beneficial ownership cap on pre-funded warrants held by EcoR1 Capital.
Zymeworks' zanidatamab wins NMPA conditional approval in China for HER2+ BTC; $20M milestone due
NMPA (China) conditionally approved zanidatamab for previously treated unresectable/metastatic HER2+ biliary tract cancer (IHC3+).
Zymeworks Q1 revenue $27.1M, net loss narrows to $22.6M; cash runway into 2H-2027
Revenue of $27.1M (vs. $10.0M in Q1 2024); net loss of $22.6M improved from $31.7M.
Zymeworks reports $122.7M net loss for 2024; Ziihera approval drives $25M milestone
Revenue $76.3M in 2024 (vs $76.0M in 2023); net loss $122.7M vs $118.7M loss prior year.
Zymeworks reports $324M cash, provides 2025-2026 pipeline milestones and cash runway into 2H-2027
Cash resources ~$324M as of Dec 31, 2024, plus $25M milestone from Jazz expected in Q1 2025.
FDA grants accelerated approval to Zymeworks' Ziihera for HER2+ BTC; $25M milestone earned
Ziihera (zanidatamab-hrii) approved for adults with previously-treated unresectable/metastatic HER2+ BTC.
Zymeworks reports 9M 2024 net loss $99.2M; cash $374.9M; completes $30M buyback; advances pipeline
Net loss $99.2M for nine months ended Sep 30, 2024 vs $104.2M loss prior year; revenue $45.3M vs $59.1M.
Zymeworks authorizes $60M share repurchase; initial $30M in H2 2024
Board authorized repurchase of up to $60M of common stock; initial $30M anticipated to begin promptly in second half of 2024.
Zymeworks Q2 2024 net loss $69.3M; cash $395.9M; zanidatamab BLA priority review by Nov 29
Net loss for H1 2024: $69.3M vs $75.5M loss in H1 2023; revenue $29.3M (down from $42.6M).
NMPA accepts zanidatamab BLA in China; Zymeworks earns $8M milestone from BeiGene
China's NMPA accepted BLA for zanidatamab in second-line HER2+ biliary tract cancer.
Zymeworks files prospectus supplement for up to $150M at-the-market offering via Cantor
Registers up to $150M in common stock for sale through Cantor Fitzgerald as sales agent (ATM offering).
Zymeworks Q1 net loss $31.7M, revenue $10M; cash $420.5M, runway into 2H27
Revenue fell to $10.0M from $35.6M YoY due to transfer of zanidatamab responsibilities to Jazz.
Zymeworks removes CFO Christopher Astle; CEO Kenneth Galbraith named interim CFO
Dr. Christopher Astle removed as SVP and CFO, including principal financial and accounting officer, effective March 31, 2024.
Zymeworks reports FY 2023 net loss of $118.7M; zanidatamab BLA initiated; cash runway into 2027
Revenue $76.0M vs $412.5M in 2022, reflecting non-recurring Jazz upfront; net loss of $118.7M vs net income $124.3M.
Zymeworks reports $455M cash, runway into 2H 2027; zanidatamab Phase 3 data expected 2024
Preliminary unaudited cash resources of $455M as of Dec 31, 2023; expected funding into second half of 2027.
appointed Mr. Oleg Nodelman, Founder and Portfolio Manager of EcoR1 (as defined below), as a director of the Company, effective as of February 17, 2025.
Mr. Hollings C. Renton submitted his resignation from the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), including as chair and member of the Board’s compensation committee, effective December 10, 2024
the Company’s board of directors (the “Board”) appointed Ms. Leone Patterson, age 61, as Executive Vice President, Chief Business Officer and Chief Financial Officer of the Company, effective upon her commencement of employment with the Company, which was anticipated to be September 1, 2024.
On August 30, 2024, Mr. Kenneth Galbraith resigned from the positions of interim Chief Financial Officer and as principal financial officer and principal accounting officer of the Company, effective as of the Start Date.
On July 19, 2024, the Board of Directors (the “Board”) of Zymeworks Inc. (the “Company”) appointed Ms. Leone Patterson, age 61, as Executive Vice President, Chief Business Officer and Chief Financial Officer of the Company, effective upon her commencement of employment with the Company, which is anticipated to be September 1, 2024
As previously reported, effective March 31, 2024 (the “Separation Date”), Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer.
the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer.
On March 31, 2024, Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.
On March 27, 2024, the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), upon recommendation from the nominating and corporate governance committee of the Board, appointed Dr. Neil Gallagher as a director of the Company, effective as of April 2, 2024.
appointed Mr. Scott Platshon, Partner of EcoR1 (as defined below), as a director of the Company, effective as of February 22, 2024.
appointed Dr. Alessandra Cesano as a director of the Company, effective as of February 8, 2024.
Dr. Kenneth Hillan submitted his resignation from the Board, including as chair and member of the nominating and corporate governance committee and as member of the research and development committee of the Board, effective February 8, 2024.
Max materiality 0.85 · Median 0.65 · Most common event other_material